Efficacy of growth hormone replacement on anthropometric outcomes, obesity, and lipids in children with optic nerve hypoplasia and growth hormone deficiency by unknown
RESEARCH Open Access
Efficacy of growth hormone replacement
on anthropometric outcomes, obesity, and
lipids in children with optic nerve
hypoplasia and growth hormone deficiency
Carly Stewart1, Pamela Garcia-Filion1, Cassandra Fink2, Anna Ryabets-Lienhard2, Mitchell E. Geffner2,3
and Mark Borchert1,3*
Abstract
Background: Hypopituitarism and obesity are causes of major lifelong morbidity in patients with optic nerve
hypoplasia (ONH). Growth hormone deficiency (GHD) affects the majority of children with ONH, though the degree
of deficiency and variability of early growth patterns range from early severe retardation to normal initial growth.
The utility of early GH replacement for improving anthropometric, body composition, and lipid outcomes in
patients with ONH and GHD, especially those with normal initial height velocity, is unknown. This study examines
the effects of GH replacement in a cohort of children with ONH and GHD.
Methods: Controlled clinical trial from 2005–2014. The study included 17 children with ONH and untreated GHD.
Those meeting criteria for growth deceleration were assigned to treatment with recombinant human growth
hormone (n = 5) while those with normal height velocity were randomized either to treatment (n = 5) or to
observation (no intervention, n = 7). Study duration was 3 years. Primary outcome measures included stature,
weight, weight-for-stature, and BMI standard deviation score (SDS) at study completion.
Results: Subjects on GH, irrespective of entry growth trajectory, grew more on average in stature than controls by
a difference of 0.98 SDS by study end; this effect persisted after adjusting for baseline overweight status. Treatment
had an effect on weight SDS only after adjusting for initial overweight status, resulting in an average increase of
0.83 SDS more than controls. Subjects who were overweight at the outset experienced greater gains in both
weight and stature SDS. Treatment had no statistically significant impact on weight-for-stature or BMI SDS. A
reduction in body fat percentage was observed in those treated, both before (−6.1 %) and after (−4.3 %)
adjustment for initial overweight status.
Conclusion: Early GH replacement has a positive effect on short-term statural outcomes in children with ONH and
GHD, even in those exhibiting normal initial linear growth. Results were less conclusive regarding treatment effects
on body composition and lipids.
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Background
Optic nerve hypoplasia (ONH) is associated with endo-
crine and metabolic manifestations, such as hypothalamic
dysregulation, hypopituitarism, and/or obesity [1–3].
Growth hormone deficiency (GHD) is the predominant
endocrinopathy, affecting as many as 70 % of children
with ONH. Classically, GHD presents as slow linear
growth, but normal growth velocity despite GHD is a
documented phenomenon among children with ONH.
Suppositions for this paradoxical “growth without growth
hormone (GH)” include the presence of alternative
growth-promoting factors and obesity itself, which may
affect as many as 50 % of patients with ONH [1, 4, 5]. It
has been reported that some ONH patients with GHD
and seemingly normal initial height velocity eventually
experience deceleration in growth, around age 3.5 years
[6]. What is unknown is whether early treatment with
GH in these patients is effective in improving height
outcomes or, secondarily, in preventing or mitigating
obesity or hyperlipidemia, benefits reported to occur in
adults with exogenous obesity and GHD after GH
replacement [1, 5, 7, 8].
The Vision Center at Children’s Hospital Los Angeles
is a referral center for diagnosis and management of
children with ONH. Using the Center’s prospective
registry of patients with ONH, we conducted a con-
trolled clinical trial to examine the effect of early GH
replacement therapy on anthropometric measurements,




Subjects were recruited from a prospective clinical regis-
try of young children with ONH. Detailed information
about the registry cohort has been previously described
[1, 9]. As part of the registry, all patients undergo a one-
time GH provocation test by glucagon stimulation prior
to 5 years of age regardless of growth status. Prior to
September 2009, the methodology for measuring GH
used radioimmunoassay (Endocrine Sciences), which
matched the WHO international reference preparation
66/217 recombinant standard; subsequent tests were
measured by immunoassay (Siemens Immulite 2000)
with calibration equaling WHO international standard
98/574. GHD was defined as a subnormal peak GH
response (<10 ng/mL). Patients with GHD and no previ-
ous GH therapy met study inclusion criteria. At enroll-
ment, subjects underwent a baseline endocrinological
evaluation prior to being assigned to a treatment group
(GH replacement versus observational control) using the
criteria described below. The study follow-up duration
was 3 years. Research was in compliance with the
Helsinki Declaration and approved by the Institutional
Review Board at Children’s Hospital Los Angeles; written
informed consent was obtained from participants’ parents
or guardians.
Study measurements
Following enrollment (baseline), subjects were seen every
4 months for sequential anthropometric measurements
and laboratory testing. The former included stature
(length for subjects < 36 months; height for those ≥ 36
months), weight, weight-for-stature (if < 121.5 cm), and
body mass index (BMI) (after age 2 years) for all subjects.
To calculate BMI for subjects aged 24–36 months, recum-
bent lengths were converted to heights by subtracting 0.8
cm [10]. Absolute measurements were normalized for age
and sex by conversion to z-scores (standard deviation
score; SDS) using Epi Info Version 3.5.4 (Centers for
Disease Control and Prevention, Atlanta, GA). Length
SDS and height SDS were combined for analyses of
stature SDS. Weight-for-stature SDS data were derived
from weight-for-length for subjects < 36 months and
weight-for-height for those ≥ 36 months. Growth velocity
(cm/year) is given as median and interquartile range; it
was not converted to SDS due to the age range of the
cohort, as no single reference provides growth velocity
percentiles for children both under and over age 2 years.
Body composition measurements of body fat per-
centage were estimated using bioelectrical impedance
(Biodynamics, Seattle, WA).
Pre-enrollment laboratory testing of GH surrogates
(IGF-I and IGFBP-3), thyroid function (free T4 by dialy-
sis), and a fasting lipid panel (total, LDL, and HDL
cholesterol, and triglycerides) was performed on all
subjects, and at each study visit for subjects in the GH
replacement group. Subsequent laboratory testing for
subjects in the control group included a fasting lipid
panel at the initial and final visits only. Additional study
data, obtained from subjects’ medical records, included
length and height measurements over the year preceding
enrollment, serum prolactin levels, the presence of other
endocrinopathies, and abnormalities identified on neu-
roradiographic imaging.
Groups
Treatment group assignment was based on subjects’
stature SDS relative to the predicted mid-parental target
height (MPTH) at baseline and subsequent classification
as having growth deceleration or normal growth. MPTH
was calculated as the average of the parents’ heights, less
2.5 inches for girls, plus 2.5 inches for boys. Criteria for
growth deceleration were either stature at least 2 SDS
below the MPTH (or the 50th percentile for height for
age in the absence of MPTH, as was the case for one
adopted subject) along with a 1 SDS drop in length/
height, or a stature at least 3 SDS below the MPTH
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along with any decrease in length/height SDS. Subjects
with growth deceleration so defined were assigned to
the GH replacement treatment group. Subjects who did
not meet these criteria were classified as having normal
growth and were randomly assigned to GH replacement
or to an observational control group (no GH replace-
ment) [11]. Data from the two GH-treated groups were
combined to assess the efficacy of this treatment
approach irrespective of entry growth velocity. For the
untreated control group, subjects were monitored for
change in growth trajectory. Control subjects were
switched (crossed over) to the GH replacement group if,
during the course of the study, they met criteria for
growth deceleration as previously defined. The study
drug was Nutropin AQ® (Genentech, South San Francisco,
CA). The starting dose for GH replacement was calculated
as 0.3 mg/kg/week and subsequently modified by a study
endocrinologist based on observed length/height velocity
and serum IGF-I levels. GH surrogates were also used to
monitor compliance with treatment.
Data analysis
The primary outcome measures were stature, weight,
weight-for-stature, and BMI SDS. The study hypotheses
were that, by the end of the three-year trial, the mean SDS
for stature would be higher and weight, weight-for-stature,
and BMI SDS would be lower for subjects in the GH
replacement group compared to the control group.
Linear regression models were constructed to analyze
the outcomes as a function of the original treatment
group assignments (GH replacement versus control)
regardless of treatment status at completion. The GH
replacement group consisted of subjects both assigned
and randomized to GH; collapsing was deemed appro-
priate after sensitivity analysis demonstrated similar
results in each of the two groups separately. The linear
regression analysis used the generalized estimating equa-
tion method to determine the average effect of GH re-
placement therapy on stature, weight, weight-for-stature,
and BMI SDS with model-based variance estimation
[12]. To account for the within-subject dependency of
repeated measurement, an exchangeable working correl-
ation matrix was specified [13]. Presence of growth
deceleration (described in the prior section) at baseline
or any point during follow-up was included as a covari-
ate to control for potential treatment bias, allowing
cross-over subjects to be analyzed by their initial group
assignment, in an intent-to-treat manner. Regression
coefficients [increase or decrease (−)], interpreted as the
average response to treatment compared to no treatment
(control), are presented with standard error (± SE) and
95 % confidence interval (95 % CI).
Body composition and lipid levels were secondary
outcomes of the efficacy of GH replacement therapy. For
body composition, analysis assessed whether body fat
percentage based on bioelectrical impedance decreased
in response to GH replacement. Analysis of body compos-
ition used the generalized estimating equation method as
previously described. Lipid levels were examined for
categorical (normal versus abnormal) changes: increase
in HDL and decrease in total and LDL cholesterol, and
triglycerides.
To examine the influence of baseline overweight status
on efficacy of GH replacement, the regression estimates
were adjusted for subject status as overweight, under-
weight, or normal weight. In accordance with the 2000
Centers for Disease Control growth charts, overweight
was defined as: weight-for-stature above the 95th per-
centile for subjects under 24 months of age or a BMI
greater than the 85th percentile for subjects 24 months
and older [14]; and underweight as weight-for-stature or
BMI below the 5th percentile.
Analyses were performed with Stata 11.0 SE (College
Station, Texas). Study data are presented using descriptive
statistics; proportions for categorical data and median
(interquartile range; IQR) for continuous data. Regression




The study included 17 participants (male = 8) enrolled at
a median age of 30 months (IQR: 24, 50). The serum GH
level after stimulation peaked at a median value of 2.3 ng/
mL (IQR: 1.4, 3.5). Table 1 presents the clinical profile of
the cohort. Treatment group assignments are illustrated
in Fig. 1. Pre-enrollment IGF-I and IGFBP-3 status are
presented in Fig. 1, though these were not considered
methodologically in our definition and diagnosis of GHD.
Table 1 Clinical profile of the study cohort (n = 17)
Number Percent
Unilateral ONH 1 6
Overweight at baseline 7 41
Underweight at baseline 2 11
Brain malformations
Hypoplastic corpus callosum 10 60
Absent septum pellucidum 7 41
Major cerebral malformation 3 18
Pituitary gland malformation 0 0
Non-visualized neurohypophysisa 3 18
Hypopituitarism (in addition to GH)
Hypothyroidism 8 47
Adrenal insufficiency 6 35
Diabetes insipidus 3 18
aAll with infundibulum visualized
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Baseline growth velocity in the group assigned to GH
replacement was 5.28 cm/year, 7.2 cm/year in those with
normal baseline growth velocity who were randomized to
GH replacement, and 7.4 cm/year in untreated controls.
Three subjects initially assigned to the control group
crossed over to the GH replacement group at follow-up
visits 3 (2 subjects) and at follow-up visit 6 (1 subject)
due to growth deceleration. All subjects underwent
routine laboratory tests for hypothyroidism, and any
observed deficiency was treated per standard of care.
There were 8 subjects (6 in GH replacement group)
with normal weight status at baseline, and all remained
so at the final study visit. Seven children were classified
as overweight at baseline; 3 normalized (2 on GH re-
placement) and 4 remained overweight (3 on GH) at the
final visit. Two subjects were underweight at baseline; 1
remained underweight and 1 was overweight at the final
visit (both crossed over to GH replacement).
Anthropometric outcomes
The treatment effects of GH replacement on outcomes
are presented in Table 2. Subjects in the GH replace-
ment group experienced a greater average increase in
stature (0.98 SDS; 95 % CI: 0.14, 1.82) than control
subjects (punadj = 0.022). The effect of GH replacement
on stature was unaffected by baseline average overweight
status (0.96; 95 % CI: 0.09, 1.82, padj = 0.030). An
increase in average weight SDS was associated with GH
replacement (0.83 SDS; 95 % CI: 0.04, 1.62) after
adjusting for baseline overweight status (padj = 0.04,
punadj = 0.251). Subjects who were overweight at baseline
experienced greater gains in both weight and stature.
Fig. 1 Assignment groups and initial characteristics at enrollment (presented as medians and interquartile ranges; IGF-I and IGFBP-3 are presented
as absolute number of subjects). * Results unavailable for one subject
Table 2 Treatment effect of GH on anthropometric and body composition outcomes
Unadjusted Adjusteda
βb ± SE 95 % CI p-value βb ± SE 95 % CI p-value
Stature SDS 0.98 ± 0.43 0.14, 1.82 0.022 0.96 ± 0.44 0.09, 1.82 0.030
Weight SDS 0.55 ± 0.48 −0.39, 1.50 0.251 0.83 ± 0.40 0.04, 1.62 0.040
BMI SDS −0.03 ± 0.57 −1.15, 1.09 0.959 0.40 ± 0.43 −0.44, 1.25 0.349
Weight-for-Stature SDS −0.12 ± 0.50 −1.11, 0.87 0.808 0.26 ± 0.35 −0.44, 0.95 0.468
Body Fat (%) −6.1 ± 2.8 −11.5, −0.6 0.030 −4.3 ± 2.3 −8.8, 0.1 0.057
aAdjusted for overweight status at baseline (normal/underweight/overweight)
bβ represents regression coefficient, interpreted as the average response [increase or decrease (−)] to GH replacement compared to no replacement
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Fig. 2 Anthropometric SDS measurements from baseline (visit 0) through follow-up (visit 9) for a) stature, b) weight, c) weight-for-stature, and d)
BMI. Treatment groups: solid line ( ) for GH replacement and dashed line ( ) for control. For subjects that started as controls, but
crossed over to treatment during follow-up, lines change from dotted to solid at the point of cross-over
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GH replacement did not affect weight-for-stature
(punadj = 0.808) or BMI (punadj = 0.959) SDS, an outcome
which persisted even after adjusting for baseline over-
weight status. The primary outcome measurements by
treatment group are illustrated in Fig. 2. Median growth
velocity in control subjects slowed to a mean of 5.7 cm/
year (IQR: 4.8, 5.9) by the final study visit (or prior to
cross-over, in applicable cases). Growth velocity at study
completion for treated subjects was 9.5 cm/year (IQR: 7.8,
9.8). Subdivided by group assignment, growth velocity was
9.7 cm/year (IQR: 9.3, 10.0) in the group assigned to GH
replacement and 8.4 cm/year (IQR: 7.0, 9.6) in those
randomized to GH.
Body composition and lipid level outcomes
Subjects’ body fat percentage showed a modest decline
regardless of adjustment for baseline overweight status
(Table 2). Prior to adjustment, GH replacement effected
a mean 6.1 % (95 % CI: −11.5 %, −0.6 %) decrease in
body fat (punadj = 0.030); after adjustment for weight, the
mean decrease was 4.3 % (padj = 0.057). Total cholesterol
levels changed from abnormal (high or low) at baseline
to normal at study completion in 4 subjects (3 on GH
replacement); LDL normalized in 4 (all on GH), and
HDL changed from low to normal in 5 (all on GH).
Total cholesterol changed from normal to high in 3 (2 on
GH) while HDL and triglycerides each changed from
normal to low in 1 subject (on GH).
Discussion
This study was designed to examine the benefit of early
GH replacement therapy on growth, body composition,
and serum lipids in young children with ONH and
GHD, and to explore whether there is any indication for
early GH treatment even in those with normal initial
growth. The results suggest that nearly all children with
ONH and GHD ultimately warrant GH replacement for
growth reasons. In this study, 6 of the 7 control subjects
were eventually assigned to treatment for growth decel-
eration. Three were assigned during the course of this
study, at a median age of 51 months, while 3 of the
remaining controls were assigned upon study comple-
tion at a median age of 60 months. This finding is
consistent with previous reports of eventual growth
deceleration in ONH patients with GHD that occurred
around age 3.5 years, despite normal initial growth
velocity [6].
Whether or not early GH replacement is indicated in
patients with normal growth depends on the efficacy of
the drug to improve their overall growth in height and/
or mitigate the problem of excess weight and its co-
morbidities. To the first end, our findings demonstrate a
positive effect of GH replacement on stature; in fact,
children randomized to GH replacement while their
growth was normal exhibited a greater response to
treatment than those assigned to GH due to growth
deceleration. The effect on body composition, however,
was less conclusive.
Researchers have proposed that GH replacement may
mitigate the development of excessive weight in children
with ONH and GHD [1, 15]. Studies of GH replacement
in obese, otherwise healthy adults have yielded various
benefits, including the reduction of total body fat and
abdominal adipose tissue; lowering of total cholesterol,
LDL, and triglycerides; increasing of HDL; and promo-
tion of overall weight loss [7, 8, 16]. Additional studies
have shown a favorable impact of GH replacement on
body composition and lipid metabolism in children with
isolated GHD [17, 18]. Further, GH replacement has
been shown to reduce body fat percentage and increase
lean body mass in patients with Prader-Willi syndrome
(PWS) and Turner syndrome who, like those with ONH,
typically manifest short stature and obesity [19, 20].
Subjects who were overweight at the outset of this
study experienced greater gains in both weight and
stature with no accompanying decrease in BMI or
weight-for-stature. On the other hand, GH replacement
was associated with a decrease in body fat percentage of
approximately 4-6 %, a finding similar to the improve-
ment in body fat percentage observed in a 12-month
randomized controlled study of GH replacement in
PWS patients, as measured by dual-energy x-ray absorp-
tiometry (DEXA) [19]. Since BMI is not validated for
our youngest study participants, nor weight-for-height
for the tallest, exclusion of these subjects’ respective data
may have impacted the detection of a treatment effect.
Observed changes in serum lipids were mostly positive;
while all subjects with abnormal total, LDL, and/or HDL
cholesterol at baseline, who were treated with GH,
attained normal levels by study completion, 2 subjects
on GH saw an unfavorable change in total cholesterol,
rendering the overall treatment effect to be inconclusive.
On the whole, these results suggest that obesity in
children with ONH is not solely attributable to GHD and
cannot be resolved simply by correcting that deficiency.
Overweight subjects’ stature responded well to GH – better,
in fact, than their normal-weight peers – but they did not
experience a decrease in BMI or weight-for-stature SDS.
Importantly, those subjects with normal initial linear
growth were markedly more overweight (7/12) than
those assigned to GH treatment (0). This points to the
central question of what causes excess weight in ONH,
and to the related question of what drives growth in
spite of GHD. Obesity in this population is likely linked
to hypothalamic dysfunction, and a result of hyperpha-
gia, hyperleptinemia or reduced leptin sensitivity, and/
or low sympathetic or dopaminergic tone [5, 21]. Obes-
ity itself is associated with suppressed GH secretion, as
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well as with hyperleptinemia [1, 22]. Accordingly, stimu-
lated GH peaks in this study were lower among over-
weight subjects compared to their non-overweight
peers. This could rightfully raise doubts as to the true
deficiency status of overweight individuals; however,
the fact that almost all of our control subjects experi-
enced eventual growth deceleration does substantiate
their GHD.
Another proposed driver of growth without GH, hy-
perprolactinemia, which may be a marker of hypothalamic
dysfunction and was found in 88 % of our subjects, has
been shown to correlate with the presence of obesity in
normal children and adults. However, an earlier study of
patients with ONH by Vedin et al. detected no association
between elevated prolactin and BMI by 5 years of
age [5, 15, 23]. Prolactin itself has been suggested to
increase serum somatomedin C/IGF-I levels in pa-
tients with craniopharyngioma or pituitary tumors
who exhibit normal IGF-I levels and normal-to-
accelerated growth following surgery; this possibility
is based on in vitro mitogenic properties of prolactin
upon mammary tissue proliferation in rodents and
cell division in Nb2 node lymphoma cells [4, 24, 25].
However, this mechanism cannot fully explain growth
without GH in ONH patients because serum pro-
lactin levels are not universally high and, when
elevated, are only mildly so. Furthermore, despite
hyperprolactinemia in some cases of ONH, circulat-
ing IGF-I levels are frequently decreased [6, 24, 26].
Insulin, which drives growth in the prenatal period,
has been cited as a possible mechanism behind the
“growth without GH” syndrome, as obesity-induced
hyperinsulinemia may stimulate hepatic production
of IGF-I. However, abnormally high levels of insulin
occur in only a subset of children with ONH, and
previous authors have ruled out hyperinsulinemia as a
growth factor in their respective studies of this patient
population [4, 6, 24, 26]. Finally, the presence of an as yet
uncharacterized circulating growth factor cannot be ruled
out [27].
The predominant limitation of this study was its small
sample size. Moreover, the unavailability of BMI for
children < 2 years and of weight-for-stature for children
> 121.5 cm in height, imposed further constraints on the
analysis. Notwithstanding, the statistical significance
achieved with such a small sample suggests that the
effects are real. BMI itself is an imperfect indicator of
obesity, though it is the preferred measure in children
[14]. Furthermore, while bioelectrical impedance is a
practical method to assess body fat in children and has
been validated against other models (densitometry and
DEXA) [28], there is significant variability in devices and
prediction algorithms, and results may be influenced by
fasting, hydration, body position, and other variables
[29]. Other methods of measurement, including waist
circumference, waist-to-hip or waist-to-height ratios,
skinfold thickness, and DEXA, may provide further reli-
ability in assessing body composition [14]. Lastly, GHD
status and eligibility were determined from only one
stimulation test (glucagon), which may seem a narrow
means of diagnosis. However, according to consensus
guidelines issued by the Growth Hormone Research
Society, which stipulate a second stimulation be used
in cases of isolated GHD, only one test – in combin-
ation with clinical, auxological, and radiological as-
sessment – suffices for patients with defined central
nervous system pathology and/or multiple pituitary
hormone deficiencies [30].
Conclusions
Eventually, nearly all patients with ONH and GHD
will require GH replacement for growth deceleration.
While early treatment appears to have a profound ef-
fect on short-term height trajectory, even in children
who are growing normally, the results of this trial are
less clear with regard to acute effects on body com-
position. Despite an observed reduction in body fat
percentage, GH replacement did not appear to im-
prove weight-for-stature or BMI in treated subjects.
This research constitutes a first attempt to study the
efficacy of GH to mitigate excess weight in ONH. Its
findings underscore the suspicion that obesity is at-
tributed to hypothalamic dysfunction and cannot be
remedied with GH replacement alone.
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